Overview

A Study to Assess Safety, Tolerability, Pharmacodynamics, Immunogenicity, Exploratory Clinical Efficacy, and Pharmacokinetics of Intravenous Infusions of E2814 in Healthy Participants and Participants With Prodromal Alzheimer's Disease (AD) to Moder

Status:
Not yet recruiting
Trial end date:
2023-02-23
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to evaluate the safety and tolerability of single and multiple ascending doses in healthy participants and participants with prodromal to moderate AD, respectively, and to demonstrate slowing in progression of tau pathology in the brain as determined by tau-positron emission tomography (PET) in participants with prodromal to moderate AD.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Eisai Inc.